Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Nitrogen-inversion rates and diffusion coefficients were measured using 1H NMR for 14 drug-like molecules. The slow nitrogen-inversion rates interconverting the enantiomers of these molecules lay within a postulated intermediate range in terms of their ability to bind to proteins bounded by diffusion constraints, potentially affecting the availability, hence efficacy, of these compounds if they were utilized as drugs. The postulated intermediate range is based on a capture-volume concept, whereby the nitrogen inversion during the time a ligand takes to pass through a volume surrounding the protein binding site, as calculated by the diffusion rate, determines if it will influence ligand binding to the protein. In the systems examined here, the measured nitrogen-inversion rates and the times required to traverse the capture volume differed by a few orders of magnitude. Potentially more consequential are intermediate nitrogen-inversion rates in epimeric cases—since the energies of the interconverting species are unequal, a heavy bias against the eutomer might occur. The implications of an intermediate nitrogen-inversion rate are significant for in silico drug design, drug efficacy, molecular modeling of drug–protein binding, pharmacokinetics, drug enantiomer evaluation, etc. Due consideration of the process should thus be taken into account for drug development directions and in vitro evaluation.

Details

Title
Can an Intermediate Rate of Nitrogen Inversion Affect Drug Efficacy?
Author
Steimbach, Raphael R 1 ; Tihanyi, Gergely 1   VIAFID ORCID Logo  ; Magalie N E Géraldy 2 ; Wzorek, Alicja 3   VIAFID ORCID Logo  ; Miller, Aubry K 4   VIAFID ORCID Logo  ; Klika, Karel D 5 

 Cancer Drug Development, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; [email protected] (R.R.S.); [email protected] (G.T.); [email protected] (M.N.E.G.); [email protected] (A.K.M.); Biosciences Faculty, University of Heidelberg, D-69120 Heidelberg, Germany 
 Cancer Drug Development, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; [email protected] (R.R.S.); [email protected] (G.T.); [email protected] (M.N.E.G.); [email protected] (A.K.M.); Bayer AG, Friedrich-Ebert Straße 217/333, D-42117 Wuppertal, Germany 
 Institute of Chemistry, Jan Kochanowski University in Kielce, Uniwersytecka 7, 25-406 Kielce, Poland; [email protected] 
 Cancer Drug Development, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; [email protected] (R.R.S.); [email protected] (G.T.); [email protected] (M.N.E.G.); [email protected] (A.K.M.); German Cancer Consortium (DKTK), D-69120 Heidelberg, Germany 
 Cancer Drug Development, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; [email protected] (R.R.S.); [email protected] (G.T.); [email protected] (M.N.E.G.); [email protected] (A.K.M.) 
First page
1753
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
20738994
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2576498498
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.